Stocks on the move (midday) = Delta-Fly Pharma, RACCOON HOLDINGS, and Nulab

Delta-Fly Pharma, Inc. <4598> - Surging sharply. After the market close on Aug. 31, Delta-Fly Pharma released an update on data analysis for the Phase 2 portion of its Phase 2/3 clinical trial in Japan of DFP-17729 (a cancer microenvironment modulator) targeting patients with unresectable, recurrent, or advanced pancreatic cancer receiving third-line or later treatment. Delta-Fly Pharma reported no adverse events affecting trial continuation have been observed to date. Under double-blind conditions, the overall survival rate across all subjects stands at 71.8%, with a median overall survival (OS) of about 7.2 months. Given that patients with advanced pancreatic cancer receiving third-line or later treatment face a poor prognosis - with a reported median OS of roughly 3-4 months - Delta-Fly Pharma noted that while the trial is ongoing and final efficacy assessments are pending, the results suggest potential to extend OS.

RACCOON HOLDINGS, Inc. <3031> - Gaining momentum and rapidly approaching a year-to-date high. After the market close on Aug. 31, RACCOON HOLDINGS reported consolidated financial results for the first quarter (May-July). Sales totaled 1.776 billion yen (up 13.9% year-on-year), while net profit came in at 226 million yen (up 31.4% year-on-year). Results were driven by efforts to expand its customer base through increased promotional investment, alongside a gain on the sale of investment securities. The strong results drew buying.

Nulab Inc. <5033> - Rising sharply to a new record high. After the market close on Aug. 31, Nulab announced that under an agreement with PR TIMES Corporation <3922>, it will provide migration support from PR TIMES' task and project management tool "Jooto" to Nulab's "Backlog." The news spurred buying. The initiative targets users of Jooto - which counts 2,379 paying companies and over 500,000 users - following an announcement on Aug. 6 that Jooto will be discontinued for general use on July 31, 2027. Nulab noted it will not inherit Jooto's business or customer contracts, with migration to Backlog subject to individual customer application.

Note: This article may contain unverified information. Please make your own investment decisions regarding the purchase and sale of stocks at your own risk.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.